General Information of Drug (ID: DMZPEHY)

Drug Name
Multi-epitope peptide melanoma vaccine Drug Info
Synonyms
Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMZPEHY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tebentafusp DMUJ1WV Gastric cancer 2B72 Approved [3]
Melanoma vaccine DMQEC6Z Melanoma 2C30 Phase 3 [4]
Multi-epitope tyrosinase/gp100 vaccine DMN68ZL Melanoma 2C30 Phase 2 [5]
Gp100:209-217(210M) peptide vaccine DM38ARE Melanoma 2C30 Phase 2 [6]
AE-08 DM7X2HK Melanoma 2C30 Phase 1 [7]
Melanoma vaccine (ALVAC) DM3HIQY Melanoma 2C30 Discontinued in Phase 2 [8]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Melanoma vaccine DMQEC6Z Melanoma 2C30 Phase 3 [4]
Polynoma-1 DM3QDA6 Melanoma 2C30 Phase 2 [9]
MKC-1106-MT DMXKOW6 Melanoma 2C30 Phase 2 [10]
Melanoma vaccine (ALVAC) DM3HIQY Melanoma 2C30 Discontinued in Phase 2 [8]
F-50040 DMMG6W5 Melanoma 2C30 Discontinued in Phase 1 [11]
Drug(s) Targeting Tyrosinase (TYR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [12]
Monobenzone DMVJS2K Vitiligo ED63.0 Approved [12]
Melanoma vaccine DMQEC6Z Melanoma 2C30 Phase 3 [4]
Polynoma-1 DM3QDA6 Melanoma 2C30 Phase 2 [9]
MKC-1106-MT DMXKOW6 Melanoma 2C30 Phase 2 [10]
Multi-epitope tyrosinase/gp100 vaccine DMN68ZL Melanoma 2C30 Phase 2 [5]
PMID29130358-Compound-Figure11(3) DMSME2B N. A. N. A. Patented [13]
Benzothiazole analog 1 DMHXFCQ Albinism EC23.2 Patented [14]
Monoamine derivative 2 DMAZ6DI Albinism EC23.2 Patented [14]
Benzimidazole derivative 3 DMY93WG Albinism EC23.2 Patented [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MART-1 melanoma antigen (MLANA) TT362RB MAR1_HUMAN Not Available [2]
Melanocytes lineage-specific antigen GP100 (PMEL) TT8MK59 PMEL_HUMAN Not Available [2]
Tyrosinase (TYR) TTULVH8 TYRO_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health.
2 Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
3 Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
4 National Cancer Institute Drug Dictionary (drug id 685201).
5 ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
6 National Cancer Institute Drug Dictionary (drug id 476335).
7 Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7.
8 Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
9 An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
10 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
11 Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
12 Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
13 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
14 Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.